...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Updated Van Leeuwenhoeck Analyst Report by Marcel Wijma 5/2/2019
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Reata had issues with Bardoxolone and CV events in previous trials, so I believe 208 would be valued at least as highly if not a great deal more. All just my opinion and speculation, but RETA worth understanding in context of CKD valuations.

 

4 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply